Similarly, several studies have examined NSCLC patients and have identified a panel of AAbs binding to rho-associated protein kinase 1, protein kinase C beta, complement factor H, c-myc, cyclin A, B1 and D1, cyclin-dependent kinase 2, MUC1, Dickkopf-related protein 1, p53, NY-ESO-1, and annexins (I and II)8–14. This evidence concerns the gene CDK2 and non-small cell lung carcinoma.